Tuberculosis drug resistance in Canada: 2006–2016 Supplementary data

ISSN 1481-8531
CCDR: Volume 43-11, November 2, 2017: Antimicrobial resistance and One Health

 

 

V GallantFootnote 1 , J VachonFootnote 1 Footnote * , W SiuFootnote 1

Affiliation

Footnotes

Footnote 1

Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, Ottawa, ON

Return to footnote 1 referrer

Footnote *

Correspondence: tb_surveillance@phac-aspc.gc.cacanbad

Return to footnote * referrer

Table 1: Total number and percentage of Mycobacterium tuberculosis complex isolates identified with any resistance, as multidrug and extensively drug resistant, by year, 2006-2016, Canada
Year Total number of reported MTBC isolates Resistant to one or more first-line drugs Multidrug-resistant TBFootnote * Extensively drug-resistant TBFootnote
n % n % n %

Abbreviations: MTBC, Mycobacterium tuberculosis complex; n, number; TB, tuberculosis
Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

2006 1,389 126 9.1 15 1.1 1 0.1
2007 1,267 133 10.5 11 0.9 0 0.0
2008 1,356 116 8.6 15 1.1 1 0.1
2009 1,331 127 9.5 18 1.4 0 0.0
2010 1,274 112 8.8 17 1.3 1 0.1
2011 1,319 139 10.5 18 1.4 1 0.1
2012 1,404 139 9.9 8 0.6 1 0.1
2013 1,371 112 8.2 14 1.0 1 0.1
2014 1,370 130 9.5 18 1.3 1 0.1
2015 1,339 139 10.4 22 1.6 0 0.0
2016 1,452 130 9.0 17 1.2 0 0.0
TOTAL 14,872 1,403 9.4 173 1.2 7 <0.1
Table 2: Overall pattern of reported tuberculosis drug resistance in Canada, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 TOTAL
n % n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: n, number; TB, tuberculosis

Footnote *

Not all isolates were tested for resistance to pyrazinamide. The percentage shown with any resistance is based on the number tested by year: 2006 = 1,080; 2007 = 991; 2008 = 1,048; 2009 = 1,042; 2010 = 1,040; 2011 = 1,197; 2012 = 1,175; 2013 = 1,187; 2014 = 1,142; 2015 =1,113; 2016=1,254

Return to footnote * referrer

Footnote †

Multidrug-resistant tuberculosis (TB) is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Total number isolates tested 1,389 100.0 1,267 100.0 1,356 100.0 1,331 100.0 1,274 100.0 1,319 100.0 1,404 100.0 1,371 100.0 1,370 100.0 1,339 100.0 1,452 100.0 14,872 100.0
Isolates tested that were susceptible 1,263 90.9 1,134 89.5 1,240 91.4 1,204 90.5 1,162 91.2 1,180 89.5 1,265 90.1 1,259 91.8 1,240 90.5 1,200 89.6 1,322 91.0 13,469 90.6
Isolates showing any resistance to first-line drugs
Any resistance to isoniazid 101 7.3 110 8.7 102 7.5 113 8.5 101 7.9 122 9.2 111 7.9 93 6.8 106 7.7 110 8.2 113 7.8 1,182 7.9
Any resistance to rifampin 24 1.7 13 1.0 19 1.4 21 1.6 18 1.4 21 1.6 10 0.7 17 1.2 24 1.8 24 1.8 18 1.2 209 1.4
Any resistance to ethambutol 12 0.9 23 1.8 13 1.0 17 1.3 10 0.8 9 0.7 4 0.3 10 0.7 6 0.4 10 0.7 10 0.7 124 0.8
Any resistance to pyrazinamideFootnote * 16 1.5 27 2.7 22 2.1 18 1.7 25 2.4 28 2.3 33 2.8 26 2.2 30 2.6 38 3.4 38 3.0 301 2.0
Total number isolates resistant to one or more first-line TB drugs 126 9.1 133 10.5 116 8.6 127 9.5 112 8.8 139 10.5 139 9.9 112 8.2 130 9.5 139 10.4 130 9.0 1,403 9.4
Monoresistant 107 7.7 111 8.8 94 6.9 98 7.4 88 6.9 119 9.0 128 9.1 93 6.8 107 7.8 114 8.5 108 7.4 1,167 7.8
Multidrug resistant 15 1.1 11 0.9 15 1.1 18 1.4 17 1.3 18 1.4 8 0.6 14 1.0 18 1.3 22 1.6 17 1.2 173 1.2
PolyresiFootnote stant 3 0.2 11 0.9 6 0.4 11 0.8 6 0.5 1 0.1 2 0.1 4 0.3 4 0.3 3 0.2 5 0.3 56 0.4
Extensively drug resistantFootnote 1 0.1 0 0.0 1 0.1 0 0.0 1 0.1 1 0.1 1 0.1 1 0.1 1 0.1 0 0.0 0 0.0 7 < 0.1
Table 3: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Alberta, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: AK, amikacin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Includes Mycobacterium africanum isolate: 1 in 2011, 2013, 2014, 2015 and 2016; 2 in 2007 and 2009, and 3 in 2010; Mycobacterium bovis: 1 in 2012, 2 in 2009, 2011 and 2013, 3 in 2015

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * 104 100.0 98 100.0 134 100.0 159 100.0 107 100.0 156 100.0 163 100.0 154 100.0 181 100.0 185 100.0 206 100.0
Isolates susceptible to all first-line TB drugs 95 91.3 92 93.9 123 91.8 145 91.2 96 89.7 133 85.3 148 90.8 140 90.9 165 91.2 164 88.6 194 94.2
Monoresistant TB
INH 7 6.7 5 5.1 8 6.0 8 5.0 6 5.6 14 9.0 10 6.1 9 5.8 11 6.1 15 8.1 7 3.4
RMP 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 1 1.0 1 1.0 0 0 3 1.9 0 0 2 1.3 3 1.8 4 2.6 0 0 3 1.6 0 0
Subtotal - Monoresistant TB 8 7.7 6 6.1 8 6.0 12 7.5 6 5.6 16 10.3 13 8.0 13 8.4 12 6.6 18 9.7 7 3.4
Polyresistant
INH & EMB 0 0.0 0 0.0 1 0.8 1.0 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & EMB & PZA 0 0 0 0 0 0 0 0 1 0.9 0 0 0 0 1 0.7 0 0 0 0 0 0
INH & PZA 0 0 0 0 0 0 1 0.6 1 0.9 0 0 1 0.6 0 0 0 0 1 0.5 0 0
Subtotal - Polyresistant 0 0.0 0 0.0 1 0.7 2 1.3 2 1.9 0 0.0 1 0.6 1 0.6 0 0.0 1 0.5 1 0.5
Multidrug-resistant TBFootnote
INH & RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA 0 0.0 0 0.0 1 0.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & RMP & EMB & PZA & SM & OFL & MOX 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & RBT 0 0.0 0 0.0 1 0.8 0 0.0 1 0.9 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM 1 1.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & RMP & ETH 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
INH & RMP & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 1.3 0 0.0 0 0.0 1 0.6 0 0.0 2 1.0
INH & RMP & PZA & SM & ETH 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & OFL & RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 0.9 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0
INH & RMP & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Multidrug-resistant TB 1 1.0 0 0.0 2 1.5 0 0.0 3 2.8 7 4.5 1 0.6 0 0.0 4 2.2 2 1.1 4 1.9
Extensively drug-resistant TBFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number isolates resistant to one or more first-line TB drugs 9 8.7 6 6.1 11 8.2 14 8.8 11 10.3 23 14.7 15 9.2 14 9.1 16 8.8 21 11.4 12 5.8
Table 4: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from British Columbia, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Includes Mycobacterium bovis isolates: 1 in 2006, 2007 and 2015; Mycobacterium africanum: 1 in 2008, 2009 and 2014; 3 in 2016; 4 in 2015; 5 in 2012 and 2013

Return to footnote * referrer

Footnote †

Routine testing for PZA not conducted in British Columbia

Return to footnote referrer

Footnote ‡

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote **

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote ** referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote *Footnote 275 100.0 231 100.0 254 100.0 239 100.0 201 100.0 194 100.0 254 100.0 213 100.0 264 100.0 231 100.0 217 100.0
Isolates susceptible to all first-line TB drugs 257 93.5 210 90.9 230 90.6 215 90.0 182 90.6 170 87.6 231 90.9 194 91.1 230 87.1 199 86.2 196 90.3
Monoresistant TB
INH 7 2.6 13 5.6 18 7.1 22 9.2 16 8.0 21 10.8 21 8.3 19 8.9 24 9.1 27 11.7 15 6.9
RMP 6 2.2 0 0.0 3 1.2 1 0.4 0 0.0 1 0.5 0 0.0 0 0.0 2 0.8 1 0.4 0 0.0
EMB 3 1.1 4 1.7 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 1 0.5
Subtotal - Monoresistant TB 16 5.8 17 7.4 21 8.3 23 9.6 18 9.0 22 11.3 21 8.3 19 8.9 26 9.8 29 12.6 16 7.4
Polyresistant TB
INH & EMB 0 0 2 0.9 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 1 0.5
INH & PZA 0 0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 2 0.8 0 0.0 2 0.9
Subtotal - Polyresistant TB 0 0.0 2 0.9 0 0.0 1 0.4 0 0.0 1 0.5 0 0.0 0 0.0 2 0.8 1 0.4 3 1.4
Multidrug-resistant TBFootnote
INH & RMP 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & KM & CM & ETH & RBT 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & PAS 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & RBT 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & KM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & OFL & ETH & RBT & PAS 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & OFL & MOX 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & RMP & EMB & SM & AK & KM & CM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0
INH & RMP & EMB & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0
INH & RMP & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 1 0.4 0 0.0
INH & RMP & PZA & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0
INH & RMP & PZA & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & RBT 0 0.0 0 0.0 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.8 0 0.0 0 0.0
INH & RMP & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0 1 0.5
Subtotal - Multidrug-resistant TB 2 0.7 2 0.9 3 1.2 0 0.0 1 0.5 1 0.5 2 0.8 0 0.0 6 2.3 2 0.9 2 0.9
Extensively drug-resistant Footnote **
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 18 6.5 21 9.1 24 9.4 24 10.0 19 9.5 24 12.4 23 9.1 19 8.9 34 12.9 32 13.9 21 9.7
Table 5: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Manitoba, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: AK, amikacin; CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Includes Mycobacterium bovis isolates: 1 in 2006 and 2007; Mycobacterium africanum: 1 in 2008

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB and PZAFootnote * 119 100.0 84 100.0 116 100.0 106 100.0 113 100.0 97 100.0 123 100.0 148 100.0 125 100.0 129 100.0 168 100
Isolates susceptible to all first-line TB drugs 113 95.0 75 89.3 111 95.7 99 93.4 99 87.6 90 92.8 113 91.9 144 97.3 120 96.0 125 96.9 156 92.3
Monoresistant TB
INH 6 5.0 7 8.3 4 3.4 4 3.8 10 8.8 5 5.2 10 8.1 4 2.7 5 4.0 3 2.3 6 3.6
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 1 1.2 0 0.0 1 0.9 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 1.8
Subtotal - Monoresistant TB 6 5.0 8 9.5 4 3.4 5 4.7 11 9.7 5 5.2 10 8.1 4 2.7 5 4.0 3 2.3 9 5.3
Polyresistant TB
INH and EMB 0 0.0 1 1.2 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH and PZA 0 0.0 0 0.0 0 0.0 1 0.9 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6
Subtotal - Polyresistant TB 0 0.0 1 1.2 0 0.0 2 1.9 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6
Multidrug-resistant TBFootnote
INH and RMP 0 0.0 0 0.0 0 0.0 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH , RMP , EMB , PZA , SM , AK , KM , CM , ETH and PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH , RMP , EMB , SM , KM and RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6
INH , RMP , PZA , ETH and RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6
INH , RMP , PZA , SM and RBT 0 0.0 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH , RMP and RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH , RMP , SM and RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.8 0 0.0
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 1 0.9 0 0.0 1 0.9 2 2.1 0 0.0 0 0.0 0 0.0 1 0.8 2 1.2
Extensively drug-resistantFootnote
INH , RMP , EMB , PZA , KM , OFL , ETH and RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 1 0.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 6 5.0 9 10.7 5 4.3 7 6.6 14 12.4 7 7.2 10 8.1 4 2.7 5 4.0 4 3.1 12 7.1
Table 6: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from New Brunswick, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB,ethambutol; ETH, ethionamide; INH, isoniazid; n, number; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; TB, tuberculosis

Footnote *

Includes one Mycobacterium africanum isolate for 2007

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * 3 100.0 5 100.0 3 100.0 10 100.0 9 100.0 5 100.0 4 100.0 3 100.0 6 100.0 7 100.0 9 100.0
Isolates susceptible to all first-line TB drugs 3 100.0 5 100.0 3 100.0 10 100.0 7 77.8 5 100.0 3 75.0 2 66.7 6 100.0 5 71.4 0 0.0
Monoresistant TB
INH 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 33.3 0 0.0 0 0.0 0 0.0
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 0 0.0 1 14.3 0 0.0
Subtotal - Monoresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 1 33.3 0 0.0 1 14.3 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote
INH & RMP & PZA & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 14.3 0 0.0
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 14.3 0 0.0
Extensively drug-resistantFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0 1 33.3 0 0.0 2 28.6 0 0.0
Table 7: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Newfoundland and Labrador, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZA 11 100.0 5 100.0 5 100.0 10 100.0 9 100.0 5 100.0 5 100.0 11 100.0 6 100.0 21 100.0 18 100.0
Isolates susceptible to all first-line TB drugs 11 100.0 5 100.0 5 100.0 10 100.0 9 100.0 5 100.0 5 100.0 11 100.0 6 100.0 21 100.0 18 100.0
Monoresistant TB
INH 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Monoresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote *
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-resistantFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Table 8: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Northwest Territories, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, numnber; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZA 4 100.0 14 100.0 13 100.0 10 100.0 5 100.0 8 100.0 6 100.0 3 100.0 2 100.0 4 100.0 4 100.0
Isolates susceptible to all first-line TB drugs 3 75.0 14 100.0 13 100.0 9 90.0 4 80.0 8 100.0 6 100.0 3 100.0 2 100.0 4 100.0 4 100.0
Monoresistant TB
INH 1 25.0 0 0.0 0 0.0 0 0.0 1 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
RMP 0 0.0 0 0.0 0 0.0 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Monoresistant TB 1 25.0 0 0.0 0 0.0 1 10.0 1 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote *
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-resistantFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 1 25.0 0 0.0 0 0.0 1 10.0 1 20.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Table 9: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Nova Scotia, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Includes one Mycobacterium bovis isolate for 2010

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * 8 100.0 5 100.0 3 100.0 7 100.0 8 100.0 7 100.0 9 100.0 9 100.0 8 100.0 7 100.0 3 100.0
Isolates susceptible to all first-line TB drugs 8 100.0 5 100.0 3 100.0 7 100.0 5 62.5 7 100.0 9 100.0 8 88.9 5 62.5 7 100.0 2 66.7
Monoresistant TB
INH 0 0.0 0 0.0 0 0.0 0 0.0 1 12.5 0 0.0 0 0.0 1 11.1 3 37.5 0 0.0 0 0.0
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 33.3
Subtotal - Monoresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 2 25.0 0 0.0 0 0.0 1 11.1 3 37.5 0 0.0 1 33.3
Polyresistant
INH & PZA 0 0.0 0 0.0 0 0.0 0 0.0 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-resistantFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0.0 0 0.0 0 0.0 0 0.0 3 37.5 0 0.0 0 0.0 1 11.1 3 37.5 0 0.0 1 33.3
Table 10: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Nunavut, 2006 to 2016
Isolate characteristics Reporting year
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZA 28 100.0 37 100.0 25 100.0 51 100.0 50 100.0 71 100.0 64 100.0 65 100.0 42 100.0 66 100.0 35 100.0 33 100.0
Isolates susceptible to all first-line TB drugs 28 100.0 37 100.0 24 96.0 51 100.0 49 98.0 70 98.6 62 96.9 65 100.0 42 100.0 66 100.0 33 94.3 33 100.0
Monoresistant TB
INH 0 0.0 0 0.0 1 4.0 0 0.0 1 2.0 1 1.4 1 1.6 0 0.0 0 0.0 0 0.0 2 5.7 0 0.0
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Monoresistant TB 0 0.0 0 0.0 1 4.0 0 0.0 1 2.0 1 1.4 2 3.1 0 0.0 0 0.0 0 0.0 2 5.7 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multi-resistant TBFootnote *
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-resistant TBFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0.0 0 0.0 1 4.0 0 0.0 1 2.0 1 1.4 2 3.1 0 0.0 0 0.0 0 0.0 2 5.7 0 0.0
Table 11: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Ontario, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * 567 100.0 538 100.0 479 100.0 488 100.0 496 100.0 507 100.0 493 100.0 511 100.0 457 100.0 480 100.0 505 100.0
Isolates susceptible to all first-line TB drugs 504 88.9 466 86.6 427 89.1 428 87.7 456 91.9 454 89.6 429 87.0 458 89.6 407 89.1 421 87.7 453 89.7
Monoresistant TB
INH 39 6.9 50 9.3 33 6.9 39 8.0 27 5.4 39 7.7 45 9.1 27 5.3 30 6.6 30 6.3 43 8.5
RMP 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 2 0.4 1 0.2 0 0.0 1 0.2
EMB 0 0.0 1 0.2 1 0.2 1 0.2 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
PZA 9 1.6 9 1.7 6 1.3 4 0.8 2 0.4 6 1.2 10 2.0 8 1.6 11 2.4 15 3.1 1 0.2
Subtotal - Monoresistant TB 49 8.6 61 11.3 40 8.4 44 9.0 29 5.8 45 8.9 57 11.6 37 7.2 42 9.2 45 9.4 45 8.9
Polyresistant TB
EMB & PZA 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & EMB 3 0.7 1 0.2 2 0.4 3 0.6 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
INH & EMB & PZA 0 0.0 0 0.0 2 0.4 2 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & PZA 0 0.0 2 0.4 0 0.0 0 0.0 1 0.2 0 0.0 1 0.2 2 0.4 1 0.2 0 0.0 0 0.0
Subtotal - Polyresistant TB 3 0.5 4 0.7 4 0.8 5 1.0 1 0.2 0 0.0 1 0.2 3 0.6 1 0.2 0 0.0 0 0.0
Multidrug-resistant TBFootnote *
INH & RMP 2 0.4 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
INH & RMP & AK & CM & RBT 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & CM & RBT 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 1 0.2
INH & RMP & EMB & PZA & AK & CM & ETH & RBT 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & CM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & ETH & RBT 0 0.0 2 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & RBT 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0
INH & RMP & EMB & PZA & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & AK & KM & CM & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0
INH & RMP & EMB & PZA & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 1 0.2 0 0.0 0 0.0 1 0.2
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
INH & RMP & EMB & PZA & SM & RBT 0 0.0 1 0.2 1 0.2 1 0.2 0 0.0 1 0.2 0 0.0 1 0.2 0 0.0 3 0.6 0 0.0
INH & RMP & EMB & RBT 1 0.4 1 0.2 1 0.2 2 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & AK & CM 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & KM & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & OFL & ETH & RBT 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & OFL & MOX & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 1 0.2
INH & RMP & ETH & RBT 2 0.4 0 0.0 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 1 0.2 0 0.0
INH & RMP & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & OFL & ETH & RBT & PAS 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2
INH & RMP & PZA & ETH & RBT 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & AK & KM & CM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0
INH & RMP & PZA & SM & ETH & RBT 0 0.0 1 0.2 1 0.2 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0
INH & RMP & PZA & SM & OFL & MOX & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 1 0.2 1 0.2 0 0.0 1 0.2
INH & RMP & RBT 1 0.2 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 2 0.4 0 0.0 0 0.0 0 0.0
INH & RMP & SM 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0
INH & RMP & SM & CM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0
INH & RMP & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0
INH & RMP & SM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0
INH & RMP & SM & KM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & SM & OFL & ETH & RBT 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & SM & RBT 0 0.0 0 0.0 3 0.6 1 0.2 1 0.2 1 0.2 1 0.2 2 0.4 1 0.2 5 1.0 0 0.0
Subtotal - Multidrug-resistant TB 10 1.8 7 1.3 7 1.5 11 2.3 10 2.0 7 1.4 5 1.0 13 2.5 6 1.3 14 2.9 7 1.4
Extensively drug-resistant TBFootnote
INH & RMP & AK & CM & OFL & ETH & RBT 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & CM & OFL & ETH & RBT & PAS 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0 0 0.0
Subtotal - Extensively drug-resistant TB 1 0.2 0 0.0 1 0.2 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0 1 0.2 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 63 11.1 72 13.4 52 10.9 60 12.3 40 8.1 53 10.5 64 13.0 53 10.4 50 10.9 59 12.3 52 10.3
Table 12: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Prince Edward Island, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZA 0 0 0 0 0 0 1 100.0 1 100.0 3 100.0 0 0 0 0 2 100.0 2 100.0 4 100.0
Isolates susceptible to all first-line TB drugs 0 0 0 0 0 0 1 100.0 1 100.0 2 66.7 0 0 0 0 2 100.0 2 100.0 4 100.0
Monoresistant TB
INH 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
RMP 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
EMB 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
PZA 0 0 0 0 0 0 0 0.0 0 0.0 1 33.3 0 0 0 0 0 0.0 0 0.0 0 0.0
Subtotal - Monoresistant TB 0 0 0 0 0 0 0 0.0 0 0.0 1 33.3 0 0 0 0 0 0.0 0 0.0 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote *
Subtotal - Multidrug-resistant TB 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
Extensively drug-resistant TBFootnote
Subtotal - Extensively drug-resistant TB 0 0 0 0 0 0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0 0 0 0 0 0 0.0 0 0.0 1 33.3 0 0 0 0 0 0.0 0 0.0 0 0.0
Table 13: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Quebec, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: AK, amikacin; CM, capreomycin; ETH, ethionamide; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Includes Mycobacterium bovis isolates: 1 in 2007, 2009, 2013 and 2014; 2 in 2006 and 2010; 3 in 2011 and 2016; 4 in 2012; Mycobacterium caprae: 1 in 2006; Mycobacterium africanum: 1 in 2006, 2008, and 2014; 2 in 2007, 2012, and 2013; 3 in 2009 and 2011; 4 in 2010; and 5 in 2015 and 2016

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB and PZAFootnote * 201 100.0 200 100.0 210 100.0 171 100.0 197 100.0 205 100.0 209 100.0 205 100.0 186 100.0 185 100.0 215 100
Isolates susceptible to all first-line TB drugs 173 86.1 177 88.5 188 89.5 156 91.2 179 90.9 180 87.8 187 89.5 187 91.2 167 89.8 167 90.3 187 87.0
Monoresistant TB
INH 21 10.4 12 6.0 15 7.1 7 4.1 11 5.6 18 8.8 13 6.2 12 5.9 10 5.4 8 4.3 17 7.9
RMP 1 0.5 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 4 2.0 4 2.0 4 1.9 2 1.2 5 2.5 6 2.9 9 4.3 4 2.0 7 3.8 6 3.2 9 4.2
Subtotal - Monoresistant TB 26 12.9 17 8.5 19 9.0 9 5.3 16 8.1 24 11.7 22 10.5 16 7.8 17 9.1 15 8.1 26 12.1
Polyresistant TB
INH and EMB 0 0.0 3 1.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
INH and PZA 0 0.0 1 0.5 1 0.5 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Polyresistant TB 0 0.0 4 2.0 1 0.5 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
Multidrug-resistant TBFootnote
INH & RMP & EMB & ETH & RBT 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
INH & RMP & EMB & PZA & RBT 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & ETH 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & KM & ETH & RBT & PAS 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & PZA & SM & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & RBT 0 0.0 1 0.5 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & EMB & SM & RBT 1 0.5 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0
INH & RMP & PZA & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0
INH & RMP & PZA & SM & AK & KM & CM 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & PZA & SM & ETH & RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & RMP & PZA & SM & KM & CM & ETH 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & RBT 0 0.0 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
INH & RMP & SM & RBT 0 0.0 0 0.0 1 0.5 2 1.2 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0
Subtotal - Multidrug-resistant TB 2 1.0 2 1.0 2 1.0 6 3.5 1 0.5 1 0.5 0 0.0 1 0.5 2 1.1 2 1.1 2 0.9
Extensively drug-reistant TBFootnote
INH , RMP , EMB , PZA , SM , AK , KM , CM , OFL , MOX , ETH and RBT 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 28 13.9 23 11.5 22 10.5 15 8.8 18 9.1 25 12.2 22 10.5 18 8.8 19 10.2 18 9.7 28 15.1
Table 14: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Saskatchewan, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZA 58 100.0 60 100.0 81 100.0 77 100.0 54 100.0 66 100.0 72 100.0 71 100.0 63 100.0 50 100.0 65 100.0
Isolates susceptible to all first-line TB drugs 57 98.3 59 98.3 79 97.5 72 93.5 51 94.4 62 93.9 68 94.4 69 97.2 60 95.2 49 98.0 62 95.4
Monoresistant TB
INH 1 1.7 1 1.7 2 2.5 3 3.9 2 3.7 4 6.1 1 1.4 1 1.4 0 0.0 0 0.0 2 3.1
RMP 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0
EMB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 4.2 1 1.4 1 1.6 1 2.0 1 1.5
Subtotal - Monoresistant TB 1 1.7 1 1.7 2 2.5 3 3.9 2 3.7 4 6.1 4 5.6 2 2.8 2 3.2 1 2.0 3 4.6
Polyresistant TB
INH & EMB 0 0.0 0 0.0 0 0.0 1 1.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & PZA 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 1 1.3 0 0.0 0 0.0 0 0.0 0 0.0 1 1.6 0 0.0 0 0.0
Multidrug-resistant TBFootnote *
INH & RMP & RBT 0 0.0 0 0.0 0 0.0 0 0.0 1 1.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
INH & RMP & SM 0 0.0 0 0.0 0 0.0 1 1.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 1 1.3 1 1.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-resistant TBFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 1 1.7 1 1.7 2 2.5 5 6.5 3 5.6 4 6.1 4 5.6 2 2.8 3 4.8 1 2.0 3 4.6
Table 15: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Yukon, 2006 to 2016
Isolate characteristics Reporting year
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n % n % n % n % n % n % n % n % n % n % n %

Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis

Footnote *

Routine testing for PZA not conducted for Yukon

Return to footnote * referrer

Footnote †

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote referrer

Footnote ‡

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Isolates tested for resistance to INH, RMP, EMB & PZAFootnote * 2 100.0 2 100.0 7 100.0 3 100.0 5 100.0 2 100.0 1 100.0 1 100.0 4 100.0 3 100.0 2 100.0
Isolates susceptible to all first-line TB drugs 2 100.0 2 100.0 7 100.0 3 100.0 5 100.0 2 100.0 1 100.0 1 100.0 4 100.0 3 100.0 2 100.0
Monoresistant TB
Subtotal - Monoresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Polyresistant TB
Subtotal - Polyresistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Multidrug-resistant TBFootnote
Subtotal - Multidrug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Extensively drug-reistant TBFootnote
Subtotal - Extensively drug-resistant TB 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Total number of isolates resistant to one or more first line drugs 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Table 16: Total number of Mycobacterium tuberculosis complex isolates by reporting and originating province/territory, 2016
Reporting province/territoryFootnote * Canada Originating province/territory
N.L. P.E.I. N.S. N.B. Que. Ont. Man. Sask. Alta. B.C. Y.T. N.W.T Nvt.

Abbreviations: Alta., Alberta; B.C., British Columbia; Man., Manitoba; N.B., New Brunswick; N.L., Newfoundland and Labrador; N.S., Nova Scotia; Nvt., Nunavut; N.W.T., Northwest Territories; Ont., Ontario; P.E.I., Prince Edward Island; Que., Quebec; Sask., Saskatchewan; Y.T., Yukon

Footnote *

Not all provinces and territories have the capacity to perform drug susceptibility testing. Those without the capacity prepare the isolates and forward them to other provincial laboratories for testing. In some instances, the laboratory that tests the sample (reporting province) sends the results to Public Health Agency of Canada (PHAC) on behalf of the originating province or territory

Return to footnote * referrer

N.L. 18 18 0 0 0 0 0 0 0 0 0 0 0 0
N.S. 7 0 4 3 0 0 0 0 0 0 0 0 0 0
N.B. 9 0 0 0 9 0 0 0 0 0 0 0 0 0
Que. 215 0 0 0 0 215 0 0 0 0 0 0 0 0
Ont. 536 0 0 0 0 3 504 0 0 0 0 0 0 29
Man. 168 0 0 0 0 0 0 168 0 0 0 0 0 0
Sask. 63 0 0 0 0 0 0 0 63 0 0 0 0 0
Alta. 216 0 0 0 0 0 0 0 2 206 0 0 4 4
B.C. 220 0 0 0 0 0 1 0 0 0 217 2 0 0
TOTAL 1,452 18 4 3 9 218 505 168 65 206 217 2 4 33
Table 17: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis isolates by province/territory of origin, 2016
Isolate characteristics Canada Originating province/territory
N.L. P.E.I. N.S. N.B. Que. Ont. Man. Sask. Alta. B.C. Y.T. N.W.T Nvt.

Abbreviations: Alta., Alberta; B.C., British Columbia; EMB, ethambutol; INH, isoniazid; Man., Manitoba; N.B., New Brunswick; N.L., Newfoundland and Labrador; N.S., Nova Scotia; Nvt., Nunavut; N.W.T., Northwest Territories; Ont., Ontario; P.E.I., Prince Edward Island; PZA, pyrazinamide; Que., Quebec; RMP, rifampin; Sask., Saskatchewan; TB, tuberculosis; Y.T., Yukon

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

INH & RMP 6 0 0 0 0 1 2 0 0 2 1 0 0 0
INH & RMP & EMB 4 0 0 0 0 0 2 1 0 1 0 0 0 0
INH & RMP & EMB & PZA 4 0 0 0 0 0 2 0 0 1 1 0 0 0
INH & RMP & PZA 3 0 0 0 0 1 1 1 0 0 0 0 0 0
Total number of Multidrug-resistant TBFootnote * 17 0 0 0 0 2 7 2 0 4 2 0 0 0
Extensively drug-resistant TBFootnote 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Table 18: Provincial/territorial breakdown by any resistance, multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in Canada, 2006 to 2016
Originating province/territory Total number of reported MTBC Isolates Resistant to one or more first-line drugs Multidrug-resistant TBFootnote * Extensively
drug-resistant TBFootnote
Number Percent (%) Number Percent (%) Number Percent (%)

Abbreviations: MTBC, Mycobacterium tuberculosis complex; TB, tuberculosis

Footnote *

Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

Ontario 5,521 618 11.2 97 1.8 5 0.1
British Columbia 2,573 259 10.1 21 0.8 0 0.0
Quebec 2,187 237 10.8 21 1.0 1 0.0
Alberta 1,647 152 9.2 24 1.5 0 0.0
Manitoba 1,328 83 6.3 7 0.5 1 0.1
Saskatchewan 717 29 4.0 2 0.3 0 0.0
Nunavut 537 7 1.3 0 0.0 0 0.0
Newfoundland and Labrador 106 0 0.0 0 0.0 0 0.0
Nova Scotia 74 8 10.8 0 0.0 0 0.0
Northwest Territories 73 3 4.1 0 0.0 0 0.0
New Brunswick 64 6 9.4 1 1.6 0 0.0
Yukon 32 0 0.0 0 0.0 0 0.0
Prince Edward Island 13 1 7.7 0 0.0 0 0.0
Canada 14,872 1,403 9.4 173 1.2 7 0.0
Table 19: Tuberculosis drug resistance by sex and age group in Canada, 2016
Age group and sex Isolates reported Resistant to one or more first-line drugs Multidrug resistantFootnote * Extensively drug resistantFootnote
Number Percent (%) Number Percent (%) Number Percent (%) Number Percent (%)
Footnote *

Multidrug-resistant tuberculosis (TB) is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant tuberculosis (TB)

Return to footnote * referrer

Footnote †

Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin)

Return to footnote referrer

< 1 Male 1 0.1 0 0.0 0 0.0 0 0.0
Female 1 0.1 0 0.0 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 2 0.1 0 0.0 0 0.0 0 0.0
1 to 4 Male 5 0.3 0 0.0 0 0.0 0 0.0
Female 6 0.4 0 0.0 0 0.0 0 0.0
Unknown 0 0.0 1 0.8 0 0.0 0 0.0
Total 11 0.8 1 0.8 0 0.0 0 0.0
5 to 14 Male 11 0.8 1 0.8 0 0.0 0 0.0
Female 11 0.8 3 2.3 1 5.9 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 22 1.5 4 3.1 1 5.9 0 0.0
15 to 24 Male 112 7.7 11 8.5 1 5.9 0 0.0
Female 95 6.5 14 10.8 3 17.6 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 207 14.3 25 19.2 4 23.5 0 0.0
25 to 34 Male 126 8.7 8 6.2 2 11.8 0 0.0
Female 160 11.0 18 13.8 2 11.8 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 286 19.7 26 20.0 4 23.5 0 0.0
35 to 44 Male 98 6.7 6 4.6 0 0.0 0 0.0
Female 84 5.8 12 9.2 4 23.5 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 182 12.5 18 13.8 4 23.5 0 0.0
45 to 54 Male 104 7.2 11 8.5 1 5.9 0 0.0
Female 71 4.9 5 3.8 1 5.9 0 0.0
Unknown 1 0.1 0 0.0 0 0.0 0 0.0
Total 176 12.1 16 12.3 2 11.8 0 0.0
55 to 64 Male 111 7.6 14 10.8 2 11.8 0 0.0
Female 49 3.4 4 3.1 0 0.0 0 0.0
Unknown 1 0.1 0 0.0 0 0.0 0 0.0
Total 161 11.1 18 13.8 2 11.8 0 0.0
65 to 74 Male 88 6.1 1 0.8 0 0.0 0 0.0
Female 75 5.2 2 1.5 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 163 11.2 3 2.3 0 0.0 0 0.0
75+ Male 135 9.3 12 9.2 0 0.0 0 0.0
Female 106 7.3 7 5.4 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 241 16.6 19 14.6 0 0.0 0 0.0
Unknown Male 1 0.1 0 0.0 0 0.0 0 0.0
Female 0 0.0 0 0.0 0 0.0 0 0.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0
Total 1 0.1 0 0.0 0 0.0 0 0.0
Total Male 792 54.5 64 49.2 6 35.3 0 0.0
Female 658 45.3 65 50.0 11 64.7 0 0.0
Unknown 2 0.1 1 0.8 0 0.0 0 0.0
TOTAL 1,452 100.0 130 100.0 17 100.0 0 0.0
Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: